ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma.

By N. Frank, A. Margaryan, Ying Huang, T. Schatton, A. Waaga-Gasser, M. Gasser, M. Sayegh, W. Sadee, M. Frank. Cancer Research, 2005

594 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways (2011, background): “Several mechanisms can be involved in CSC chemoresistance and radioresistance, including expression of the ATP-binding cassette superfamily of active drug transporters”
Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment (2009, background): “ABCB5 was found to be expressed on a distinct subset of chemoresistant CD133 melanoma cells (32), and its selective targeting caused tumor growth inhibition in xenograft models (11).”
The therapeutic promise of the cancer stem cell concept. (2010, background): “The doxorubicin chemoresistance mediator ABCB5 (93, 111) is expressed in human breast cancer and was substantially downregulated after differentiation therapy in these studies (124), raising the possibility that loss of more primitive and doxorubicin-resistant ABCB5-expressing breast cancer cell”